The COURAGE trial: is there still a role for PCI in stable coronary artery disease?
Spencer B King III
Correspondence The Fuqua Heart Center, Piedmont Hospital, Suite 705, 1938 Peachtree Road NW, Atlanta, GA 30309, USA
Email spencer.king@piedmont.org
This article has no abstract so we have provided the first paragraph of the full text.
The COURAGE trial headlines could be taken as a reason to markedly curtail PCI, or dismissed as being representative of a flawed, highly selective study. We should, however, take a closer look at the trial and what the findings mean for clinical practice. The study was not actually a comparison of PCI and medical therapy. Instead, within a setting of good medical care, it compared routine PCI with deferred, selective PCI for patients with symptom progression or ischemia.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
